분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-05-25 10:42:32 , Hit : 2328
 Vertex hepatitis C drug OK'd, promising more cures

By Lewis Krauskopf and Bill Berkrot

NEW YORK | Mon May 23, 2011 5:51pm EDT

NEW YORK (Reuters) - Vertex Pharmaceuticals Inc's highly anticipated hepatitis C drug won U.S. approval, promising far higher cure rates for the liver-destroying disease and setting up a head-to-head marketing battle with a rival new medicine from Merck & Co.

Incivek, a pill also known as telaprevir, is poised to help transform treatment of hepatitis C by nearly doubling the chances of curing the serious liver disease compared with current standard treatments. Some industry analysts project Incivek sales will top $5 billion a year.

Vertex set a wholesale price of $49,200 for a 12-week regimen of Incivek, which works in combination with current standard drugs pegylated interferon and ribavirin. The older treatments are then continued for as few as another 12 weeks.

Merck's recently approved Victrelis has a wholesale price of $1,100 per week, or between $26,400 and $48,400 for a course of treatment, depending on needed duration.

Vertex said it was initiating a co-pay assistance program that would reimburse the out-of-pocket costs for the majority of patients covered by commercial health insurance, which accounts for about 60 percent of its expected patient mix.

The approval, which the Food and Drug Administration announced on Monday, was widely expected after an advisory panel unanimously recommended the drug last month.

Vertex said it anticipated approval late this year for Europe, where Johnson & Johnson holds the marketing rights.

Vertex said Incivek, its first commercial product, would arrive in pharmacies this week. The company expects to become profitable next year.

Chief Executive Officer Matthew Emmens said the Incivek approval was the culmination of a $4 billion investment for developing the drug from the beginning in its own labs.

Joshua Boger, Vertex founder and former CEO who pinned the company's fortunes on telaprevir long before the drug had proved itself in clinical trials, said it was "a great day for patients that we at Vertex envisioned almost 18 years ago."

In clinical studies, as many as 79 percent of patients taking Incivek experienced a sustained virologic response -- which is tantamount to a cure. Older drugs cure only about 40 percent of patients.

INCIVEK VS VICTRELIS

Doctors say thousands of hepatitis C patients have been delaying treatment in anticipation of the new medicines because the older drugs had to be taken for 48 weeks, often caused flu-like symptoms and offered a disappointing cure rate.

Incivek offers the potential of cutting the treatment duration to 24 weeks for many patients, while Victrelis can cut treatment down to 28 weeks for some.

About 170 million people around the world are infected with hepatitis C, some 3.2 million of them in the United States. The blood-borne disease can lead to liver cancer, cirrhosis, liver transplants and death.

On May 13, the FDA approved Victrelis, which works the same way as Incivek and is also taken with the older medicines.

Analysts expect Incivek to eventually control more of the market because it has shown a higher cure rate. Victrelis had a 66 percent cure rate in late-stage studies, although the new drugs have not been tested against each other.

"There are now two important new treatment options for hepatitis C that offer a greater chance at a cure," said Edward Cox, director of the FDA drug center's office of antimicrobial products.

The most commonly reported side effects with Incivek include rashes and anemia, the FDA said. The rash can be serious and can require stopping Incivek or all three drugs in the treatment regimen.

The Incivek label says only 4 percent of patients reported a severe rash, Sanford Bernstein analyst Geoffrey Porges said.

"We do not see this as a significant limitation to adoption," Porges said.

Some analysts have projected market share splits of 70-30 or higher in favor of Vertex, including Jason Kantor of RBC Capital Markets.

"At the end of the day Vertex has the better drug profile, simpler drug to use and I still expect Vertex to get the lion's share of the market," Kantor said.

Last week Merck struck a deal with Roche Holding AG, which will co-promote Victrelis in the United States. Roche and Merck dominate the market for interferons.

"There's certainly some pricing strategies around interferons that Merck and Roche may be able to use," Brean Murray, Carret & Co analyst Brian Skorney said.

Vertex shares closed up 81 cents, or 1.5 percent at $55.81 on Nasdaq, while Merck shares fell 16 cents to $36.90 on the New York Stock Exchange.

(Additional reporting by Toni Clarke in Boston; editing by John Wallace, Maureen Bavdek and Lisa Von Ahn)








707   Hepatitis C Drugs Await FDA Approval  이성욱 2011/04/26 2301
706   The ghost of personalized medicine  이성욱 2011/07/21 2301
705   유방암의 cyclin D1과 마이크로 알앤에이의 연관성  이성욱 2013/12/05 2305
704   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2306
703   날씬한 마우스의 장내 미생물은 비만 치료제  이성욱 2013/09/11 2306
702   Tumours grow their own blood vessels  이성욱 2010/11/25 2308
701   이제 미리 초기 간암 전구세포 확인  이성욱 2013/10/14 2309
700   Researchers discover a switch that controls stem cell pluripotency  이성욱 2011/09/21 2317
699   What Do Worms Have to Do With Asthma?  이성욱 2011/02/25 2318
698   Scientists use mRNA molecules to create iPS cells  이성욱 2010/10/02 2319
697   Scientists Show How Men Amp Up Their X Chromosome  이성욱 2011/03/07 2319
696   Basel Declaration defends animal research  이성욱 2010/12/10 2320
695   항생제 내성세균의 대안으로 부활하고 있는 박테리오파지 요법  이성욱 2014/06/06 2321
694   그림의 떡 - 한 알에 1,000달러짜리 C형간염 신약 소포스부비어  이성욱 2013/12/20 2323
693   Treatment of Common Virus Can Reduce Tumour Growth, Study Suggests  이성욱 2011/10/04 2325
692   암 줄기세포의 항암제 저항성과의 연관성  이성욱 2014/04/23 2325
691   RNA Controls Splicing During Gene Expression, Further Evidence of 'RNA World' Origin in Modern Life  이성욱 2013/11/07 2327
  Vertex hepatitis C drug OK'd, promising more cures  이성욱 2011/05/25 2328
689   'Patent trolls' target biotechnology firms  이성욱 2011/10/03 2328
688   인간 난자의 DNA 염기서열을 해독하는 비침습적 방법 개발  이성욱 2013/12/23 2333

[이전 10개] [1]..[21][22][23][24][25][26][27][28] 29 [30]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN